Time and dose-related changes in radiological lung density after concurrent chemoradiotherapy for lung cancer

Lung Cancer

Volumn 74, Issue 3, 2011, Pages 451-456

  Phernambucq, Erik C J ^a   Palma, David A ^a,b   Vincent, Andrew ^c   Smit, Egbert F ^a   Senan, Suresh ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Concurrent chemoradiotherapy; CT scan; Lung cancer; Radiation induced lung disease; Toxicity scoring

Indexed keywords

CISPLATIN; ETOPOSIDE; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER REGISTRY; CANCER SIZE; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DENSITY; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LUNG VOLUME; MALE; PRIORITY JOURNAL; RADIATION DOSE; RADIOLOGICAL LUNG DENSITY; TIME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CISPLATIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIATION PNEUMONITIS; RADIOTHERAPY DOSAGE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80755132147     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.05.010     Document Type: Article

References (19)

1. Auperin A., Le Pechoux C., Rolland E., Curran W.J., Furuse K., Fournel P., et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:2181-2190.
2. Kelly K., Chansky K., Gaspar L.E., Albain K.S., Jett J., Ung Y.C., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008, 26:2450-2456.
3. Radiation Therapy Oncology Group. A randomized phase III comparison of standard-dose (60Gy) versus highdose (74Gy) conformal radiotherapy with concurrent and consolidation carboplatin/paclitaxel +/- cetuximab (IND #103444) in patients with stage IIIA/IIIB non-small cell lung cancer. RTOG 0617/NCCTG N0628/CALGB 30609/ECOG R0617. Study protocol available online at: [last accessed 07.03.2011]. http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0617.
4. Senan S., Cardenal F., Vansteenkiste J., Stigt J., Akyol F., De Neve W., et al. A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer. Ann Oncol 2011, 22:553-558.
5. O'Rourke N., Roque I.F.M., Farre Bernado N., Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2010, CD002140.
6. Hope A.J., Lindsay P.E., El Naqa I., Alaly J.R., Vicic M., Bradley J.D., et al. Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. Int J Radiat Oncol Biol Phys 2006, 65:112-124.
7. Choi Y.W., Munden R.F., Erasmus J.J., Park K.J., Chung W.K., Jeon S.C., et al. Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis. Radiographics 2004, 24:985-997.
8. De Ruysscher D., Faivre-Finn C., Nestle U., Hurkmans C.W., Le Pechoux C., Price A., et al. European organization for research and treatment of cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol 2010, 28:5301-5310.
9. Ghobadi G., Hogeweg L.E., Faber H., Tukker W.G., Schippers J.M., Brandenburg S., et al. Quantifying local radiation-induced lung damage from computed tomography. Int J Radiat Oncol Biol Phys 2010, 76:548-556.
10. Mah K., Van Dyk J. Quantitative measurement of changes in human lung density following irradiation. Radiother Oncol 1988, 11:169-179.
11. Kahan Z., Csenki M., Varga Z., Szil E., Cserhati A., Balogh A., et al. The risk of early and late lung sequelae after conformal radiotherapy in breast cancer patients. Int J Radiat Oncol Biol Phys 2007, 68:673-681.
12. Ma J., Zhang J., Zhou S., Hubbs J.L., Foltz R.J., Hollis D.R., et al. Regional lung density changes after radiation therapy for tumors in and around thorax. Int J Radiat Oncol Biol Phys 2010, 76:116-122.
13. Park K.J., Chung J.Y., Chun M.S., Suh J.H. Radiation-induced lung disease and the impact of radiation methods on imaging features. Radiographics 2000, 20:83-98.
14. Palma D.A., van Sornsen de Koste J.R., Verbakel W.F.A.R., Senan S. A new approach to quantifying lung damage after stereotactic body radiation therapy. Acta Oncol 2011, 50:509-517.
15. Palma DA, van Sornsen de Koste J, Verbakel WF, Vincent A, Senan S. Lung density changes after stereotactic radiotherapy: a quantitative analysis in 50 patients. Int J Radiat Oncol Biol Phys, in press.
16. Phernambucq E.C., Spoelstra F.O., Verbakel W.F., Postmus P.E., Melissant C.F., Maassen van den Brink K.I., et al. Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity. Ann Oncol 2011, 22:132-138.
17. Spoelstra F.O., Senan S. Novel tools in radiotherapy. Ann Oncol 2008, 19(Suppl. 7):vii294-vii299.
18. Barriger R.B., Fakiris A.J., Hanna N., Yu M., Mantravadi P., McGarry R.C. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel. Int J Radiat Oncol Biol Phys 2010, 78:1381-1386.
19. Saunders M., Dische S., Barrett A., Harvey A., Griffiths G., Palmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART steering committee. Radiother Oncol 1999, 52:137-148.